SCHEMBL23852012

SCHEMBL23852012

CS(=O)(=O)N1CCN(C2CCC(N)CC2)CC1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.60
KDM4E B2RXH2 5/20 0.60
RECQL P46063 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ALOX15 P16050 1/20 0.42
HRH3 Q9Y5N1 2/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPK1 P28482 2/20 0.40
MAPT P10636 1/20 0.40
IRAK4 Q9NWZ3 2/20 0.38
GAA P10253 1/20 0.38
POLB P06746 1/20 0.38
TP53 P04637 1/20 0.37
CYP2D6 P10635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11942151 1.00 ALDH1A1 (0.60) ALDH1A1KDM4ERECQLSMN1; SMN2ALOX15
SCHEMBL2104955 0.90 ALDH1A1 (0.70) ALDH1A1KDM4ERECQLSMN1; SMN2ALOX15
SCHEMBL14097292 0.82 ALDH1A1 (0.61) ALDH1A1KDM4ERECQLSMN1; SMN2HRH3
SCHEMBL363726 0.79 TP53 (0.48) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL13713287 0.78 ALDH1A1 (0.57) ALDH1A1KDM4ERECQLSMN1; SMN2ALOX15
SCHEMBL16372109 0.78 PHGDH (0.32) ALDH1A1KDM4EALOX15HRH3
SCHEMBL23862929 0.78 ALDH1A1 (0.57) ALDH1A1KDM4ERECQLSMN1; SMN2ALOX15
Hydrochloric Acid SCHEMBL928103 0.77 TP53 (0.47) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL19288712 0.77 ALDH1A1 (0.56) ALDH1A1KDM4ERECQLSMN1; SMN2ALOX15
SCHEMBL311214 0.77 ALDH1A1 (0.56) ALDH1A1KDM4ERECQLSMN1; SMN2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378250-B2 Tricyclic compound as IRAK4 inhibitor KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-08-05 US disclosed
EP-3885348-B1 NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR KOREA RES INST CHEMICAL TECH (KR) 2025-02-12 EP disclosed
CN-113227095-B Novel tricyclic compounds as IRAK4 inhibitors 韩国化学研究院 2024-07-05 CN disclosed
US-20220009933-A1 NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2022-01-13 US disclosed
EP-3885348-A1 NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR Korea Research Institute of Chemical Technology (KR) 2021-09-29 EP disclosed
EP-3885348-A1 NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR Korea Research Institute of Chemical Technology (KR) 2021-09-29 EP disclosed
CN-113227095-A Novel tricyclic compounds as IRAK4 inhibitors 韩国化学研究院 2021-08-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378250-B2 Tricyclic compound as IRAK4 inhibitor IRAK4, IRAK1, IRAK2 ALDH1A1 2912/4885KDM4E 326/4885RECQL 3162/4885
US-20220009933-A1 NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR IRAK4, IRAK1, IRAK2 ALDH1A1 3048/4885KDM4E 363/4885RECQL 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.